PASCALINE CLERC

About PASCALINE CLERC

Pascaline Clerc currently holds a senior leadership position at Inventiva, where she serves as Executive Vice President, Strategy and Corporate Affairs and sits on the company’s Executive Committee. In this role, she oversees strategic positioning, corporate affairs, institutional communications and stakeholder engagement. Her remit is particularly important at a time when Inventiva is concentrating its resources on the development of lanifibranor, the company’s lead asset in MASH/NASH. Her internal progression reflects a broader elevation of responsibilities after initially joining the group in a Global External Affairs capacity. Clerc’s background combines scientific training with strong experience in public policy and stakeholder engagement. Inventiva describes her as having more than 20 years of experience spanning academia, government, non-profit organizations and biotechnology, with a specific focus on the MASH/NASH space. Before joining Inventiva, she led global public policy strategy and patient advocacy engagement for a major biotechnology company active in the same therapeutic area. That experience gave her deep exposure to advocacy strategy, corporate communications, patient engagement, and the alignment of scientific narratives with regulatory and societal expectations. Academically, Pascaline Clerc holds a Master’s degree in biochemistry, cell biology and molecular biology, as well as a PhD in cell biology from Université Grenoble-Alpes in France. She also received an AAAS Science and Technology Policy Fellowship, completed at the U.S. Department of the Interior, adding an international public-policy dimension to her profile. This combination of rigorous scientific training and policy experience is particularly valuable in biopharma, where clinical development, public positioning and regulatory credibility must be tightly coordinated. At Inventiva, she plays a key role in supporting the company’s external narrative and in strengthening its relationships with investors, regulators, partners and patient communities. In a listed life sciences company, that kind of leadership is critical: it helps translate complex clinical progress into a clear corporate story and reinforces trust across stakeholder groups. Her role also highlights the growing importance of strategy and corporate affairs functions in late-stage biotechnology companies navigating high-stakes development programs and market expectations.